Search clinical trials for: BMS-986322

Total 3147 results

M.D. Anderson Cancer Center

Active, not recruiting

BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers

Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Metastatic Carcinoma in the Liver | Metastatic Carcinoma in the Lung | Metastatic Malignant Neoplasm in the Thoracic Cavity

United States
Bristol-Myers Squibb

Active, not recruiting

A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors

Advanced Cancer

Italy, Australia, United States, Spain, Romania, Argentina, Canada, Chile, Finland, Germany, Poland
Bristol-Myers Squibb

Terminated

An Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in Participants With Solid Cancers That Have Spread or Cannot be Removed

Advanced Cancer

United States
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

A Safety Study of Lirilumab in Combination With Nivolumab or in Combination With Nivolumab and Ipilimumab in Advanced and/or Metastatic Solid Tumors

Advanced Cancer

Japan
Bristol-Myers Squibb

Completed

A Study to Assess the Effect of BMS-986142 on Pharmacokinetics (PK) of Probe Substrates

Rheumatoid Arthritis

United States
Bristol-Myers Squibb
Exelixis

Terminated

A Study of BMS-863233 in Patients With Advanced and/or Metastatic Solid Tumors

Metastatic Cancer | Advanced Solid Cancers

United States, Canada, France
Aegerion Pharmaceuticals, Inc.

Completed

Long Term, Follow-on Study of Lomitapide in Patients With Homozygous Familial Hypercholesterolemia

Familial Hypercholesterolemia

United States, Canada, Italy, South Africa
Bristol-Myers Squibb

Completed

Three-year Follow-up Study of Subjects Who Participated in a Previous Lambda (BMS-914143) Chronic Hepatitis C Clinical Trial

Hepatitis C

Argentina, Australia, Belgium, France, Germany, Italy, United States, Canada, Spain, Mexico, Austria, Poland, Netherlands, Korea, Republic of, Puerto Rico, New Zealand, Finland, Greece, Romania
Vanda Pharmaceuticals

Completed

Effects of Smoking, Age and Body Size on Pharmacokinetics, Safety and Tolerability on Tasimelteon in Healthy Subjects

Healthy Volunteers

United States
InspireMD

Completed

Safety and Efficacy Study of MGuard Stent After a Heart Attack (MASTER)

Myocardial Infarction

Poland, South Africa
Bristol-Myers Squibb

Completed

A Study to Compare the Taste and Levels in Blood Plasma of BMS-986165 When Taken as Different Formulations by Healthy Adult Participants

Healthy Participants

United States
Bristol-Myers Squibb

Withdrawn

Phase 2b Study of BMS-986094 and Daclatasvir, With or Without Ribavirin for the Treatment of Patients With Chronic Hepatitis C

Hepatitis C Virus

United States
Juno Therapeutics, a Subsidiary of Celgene

Active, not recruiting

A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma

Multiple Myeloma

United States
Ronald Levy
Bristol-Myers Squibb

Completed

SD-101 and BMS-986178 in Treating Patients With Advanced or Metastatic Solid Malignancies

Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Extracranial Solid Neoplasm

United States
Bristol-Myers Squibb

Completed

A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer

Italy, United States, Argentina, Belgium, Germany, Israel, Poland, Spain, Turkey, Australia, Chile, France
Bristol-Myers Squibb

Withdrawn

Safety Study of Anti-Programmed Death-Ligand 1 in Hematologic Malignancy

Multiple Myeloma | Hodgkin Lymphoma | Non-Hodgkin's Lymphoma | Chronic Myelogenous Leukemia
Bristol-Myers Squibb

Completed

An Ascending Dose Study of BMS-986259 to Study Safety in Healthy Participants

Healthy Participants

United Kingdom, Netherlands
Bristol-Myers Squibb

Terminated

Study of BMS-663513 in Patients With Advanced Cancer

Tumors

United States, Canada, France
Bristol-Myers Squibb

Completed

Multiple Dose Japanese Bridging Study

Alzheimer Disease

United States
Bristol-Myers Squibb

Active, not recruiting

A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers

Melanoma | Cancer

United States, Poland, Italy, Belgium, France, Australia, Canada, Germany, Spain, Sweden, Switzerland, United Kingdom
Bristol-Myers Squibb

Completed

An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma

Melanoma | Skin Cancer

United States, Canada, Netherlands, Spain, Australia, Italy, Japan, Germany, Ireland, United Kingdom, Czechia, Switzerland, Poland, France, Greece, New Zealand
National Cancer Institute (NCI)

Completed

BMS-214662 Plus Trastuzumab in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Bristol-Myers Squibb

Completed

Study to Assess the Way the Body Absorbs, Distributes, Breaks Down and Eliminates Radioactive BMS-986278 in Healthy Male Participants

Healthy Volunteers

United States
Bristol-Myers Squibb

Terminated

A Study of BMS-663513 Administered in Combination With Chemotherapy to Subjects With Advanced Solid Malignancies

Advanced Solid Malignancies

United States, Canada
Bristol-Myers Squibb

Completed

Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BMS-986120 in Healthy Subjects and the Effects of Co-Administration of Midazolam and BMS-986120

Healthy Adult Volunteers

United States
Sumitomo Pharma Co., Ltd.

Completed

A Pharmacodynamics and Safety Study of DSP-9632P in Patients With Levodopa-Induced Dyskinesia in Parkinson's Disease

Parkinson's Disease | Levodopa-induced Dyskinesia

Japan
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed Multiple Myeloma

Multiple Myeloma

United States
Janssen Research & Development, LLC
Bristol-Myers Squibb

Recruiting

A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS)

Acute Coronary Syndrome

Taiwan, Korea, Republic of, United States, Italy, South Africa, Belgium, Argentina, Israel, Malaysia, Romania, Serbia, China, Australia, Netherlands, United Kingdom, Denmark, Czechia, Hungary, Japan, France, Canada, Bulgaria, Spain, T... and more
Janssen Research & Development, LLC
Bristol Myers Squibb Company (BMS)

Recruiting

A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE (LIBREXIA-STROK)

Ischemic Stroke; Ischemic Attack, Transient

Italy, United States, Hong Kong, Japan, Taiwan, Korea, Republic of, Israel, United Kingdom, Argentina, Belgium, New Zealand, Canada, Germany, Denmark, Mexico, Croatia, France, Australia, Brazil, China, Czechia, Hungary, Netherlands, S... and more
Bristol-Myers Squibb

Active, not recruiting

A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)

Myelofibrosis

Italy, Spain, United States, Australia, France, Germany, Greece, Hungary, Israel, Korea, Republic of, Poland, Romania
R-Pharm

Terminated

Phase 1 Trial of Oral Ixabepilone

Advanced Solid Tumors

United States
R-Pharm

Completed

A Phase II, Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer

Metastatic Pancreatic Cancer

United States
Bristol-Myers Squibb
Clovis Oncology, Inc.

Completed

A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer (FRACTION-GC)

Advanced Gastric Cancer

United States, Israel, Netherlands, Canada, Italy, Australia, Germany, Singapore, Switzerland
Bristol-Myers Squibb

Completed

Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus

Lupus

Taiwan, United States, Canada, Italy, Mexico, South Africa, Korea, Republic of, Japan, France, Spain, Argentina, Hungary, Colombia, Peru, Poland, Puerto Rico, Romania, Brazil, Chile, Germany, Lebanon, Netherlands, Russian Federation
Thomas Jefferson University
Bristol-Myers Squibb

Active, not recruiting

Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and Neck

Larynx | Squamous Cell Carcinoma | Lip | Oral Cavity Squamous Cell Carcinoma | Pharynx

United States
Bristol-Myers Squibb
Medarex

Completed

Drug-Drug Interaction - 3 Arm - Carboplatin/Paclitaxel, Dacarbazine

Advanced Melanoma

United States
Celgene

Active, not recruiting

A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

Multiple Myeloma

United States, Canada, Italy, Czechia, Denmark, France, Germany, Greece, Spain
R-Pharm

Completed

A Randomized Phase 2 Study of Ixabepilone Plus Carboplatin and Paclitaxel Plus Carboplatin in Advanced Nonsmall-Cell Lung Cancer

Advanced/Metastatic Non-Small Cell Lung Cancer

Germany, Korea, Republic of, Russian Federation, Taiwan, Australia, Italy, France, United States, Argentina, Spain
Biohaven Pharmaceuticals, Inc.

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Participants With Spinal Muscular Atrophy (RESILIENT)

Neuromuscular Diseases | Spinal Muscular Atrophy | SMA

United States, Netherlands, United Kingdom, Spain, Czechia, Belgium, Germany, Italy, Poland
RWTH Aachen University

Withdrawn

The Influence Cirrhosis of the Liver on the Coronary Re-stenosis (LTX- Stent Study)

Cirrhosis of the Liver | Re-stenosis
Bristol-Myers Squibb

Completed

UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis

Hepatitis C

United States, Australia, Canada, France
Bristol-Myers Squibb

Recruiting

Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease (TargetTau-1)

Alzheimer Disease, Early Onset

United States, Australia, Belgium, Canada, Denmark, France, Japan, Korea, Republic of, Netherlands, Poland, Singapore, Spain, Sweden, United Kingdom
The University of Hong Kong

Not yet recruiting

Integrative Body-Mind-Spirit Group Intervention for Infertile Couples

Infertility

Hong Kong
Bristol-Myers Squibb

Completed

A Study to Evaluate the Drug Levels, Safety, and Tolerability of BMS-986036 in Participants With Normal Liver Function and Participants With Moderate and Severe Liver Impairment

Moderate Liver Impairment | Severe Liver Impairment

United States
Bristol-Myers Squibb

Completed

A Single-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-986263 in Participants With Varying Degrees of Liver Impairment

Hepatic Impairment

United States
Bristol-Myers Squibb

Completed

Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications

Chronic Hepatitis C

France, United States, Puerto Rico
Bristol-Myers Squibb

Completed

Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin (D-LITE)

Hepatitis C

France, Germany, Italy, Japan, United States, Australia, Puerto Rico, Spain, New Zealand
M.D. Anderson Cancer Center

Active, not recruiting

Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Malignancies

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Advanced Malignant Solid Neoplasm | Stage III Lung Cancer AJCC v8 | Advanced Lung Carcinoma | Metastatic Lung Carcinoma | Stage IV Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Metastatic Malignant... and other conditions

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
Bristol-Myers Squibb

Recruiting

Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma

United States
Timothy Morgan, MD
Bristol-Myers Squibb; National Cancer Institute (NCI); VA Long Beach Healthcare...

Completed

Rapid Hepatitis C Elimination Trial- A Pilot Study of Daclatasvir/Asunaprevir/BMS-791325 With or Without Ribavirin To Treat Hepatitis C Virus (RHACE 1)

Hepatitis C

United States

Search clinical trials for: BMS-986322

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Suriname

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations